Drug intelligence / Profile preview

Meta19.01

Development stage: Preclinical
Lead developer: Metagenics

Overview

Meta19.01 is a specialized nutraceutical developed by Metagenics Europe. It is composed of plant extracts, vitamins, and fish oil. The product is currently being investigated in a single-center, randomized, double-blind, placebo-controlled study to evaluate its efficacy and tolerability for the management of endometriosis.

Beyond the preview

Go deeper on Meta19.01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meta19.01.

Explore the full profile